Corticosteroids for Children With Febrile Urinary Tract Infections



Status:Completed
Conditions:Infectious Disease, Urology, Urinary Tract Infections
Therapuetic Areas:Immunology / Infectious Diseases, Nephrology / Urology, Other
Healthy:No
Age Range:Any - 6
Updated:10/5/2018
Start Date:September 2011
End Date:March 30, 2018

Use our guide to learn which trials are right for you!

In this study the investigators will determine whether corticosteroids given at the time of
urinary tract infection help prevent permanent damage to the kidneys.

Because host inflammatory response is the final and most important step in the formation of
renal scars, the use of anti-inflammatory agents may be the best strategy to reduce renal
scarring. In animal studies, the use of corticosteroids has been shown to be effective in
preventing post-pyelonephritic scarring. We will conduct a randomized, double-blind,
placebo-controlled trial to determine the efficacy of 3 days of daily adjuvant dexamethasone
on the incidence of renal scarring 4 to 6 months after a first febrile UTI. We hypothesize
that the proportion of children with UTI who develop renal scarring will be lower among
children who are treated with both dexamethasone and antibiotics as compared with children
treated with antibiotics alone.

Inclusion Criteria:

- Age: 2 months to 6 years

- Pyuria (≥10 WBC/mm3 in an uncentrifuged specimen or ≥5 WBC/hpf in a centrifuged
specimen or ≥1+ leukocyte esterase on dipstick)

- Fever: documented temperature of at least 101 °F or 38.3°C, measured anywhere on the
body either at home or at doctor's office within 24 hours of diagnosis

Exclusion Criteria:

- Other concurrent systemic bacterial infection(s) such as meningitis or pneumonia;

- Planned admission to intensive care unit;

- Known bacteremia;

- Previous protocol defined UTI;

- Known major urinary tract anomalies (severe hydronephrosis, ureterocele, urethral
valve, solitary or profoundly small kidney, multicystic dysplastic kidney, neurogenic
bladder, pelvic or fused kidney);

- Congenital/acquired immunodeficiency;

- Bag urine collection

- Chronic diseases that could potentially interfere with response to therapy, such as
chronic gastrointestinal conditions (i.e. malabsorption, inflammatory bowel disease),
liver/kidney failure;

- Allergy to dexamethasone

- Antibiotic use within 7 days of enrollment (except if given in the last 48 hours)

- Systemic use of corticosteroids or other immunomodulating agents within 14 days of
enrollment

- History of Kawasaki disease

- Sickle cell disease (not trait)
We found this trial at
5
sites
Madison, Wisconsin 53792
Principal Investigator: Ellen R Wald, MD
?
mi
from
Madison, WI
Click here to add this to my saved trials
Columbus, Ohio 43205
Principal Investigator: Daniel M Cohen, MD
?
mi
from
Columbus, OH
Click here to add this to my saved trials
3414 Fifth Avenue
Pittsburgh, Pennsylvania 15213
Principal Investigator: Nader Shaikh, MD
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Providence, Rhode Island 02903
?
mi
from
Providence, RI
Click here to add this to my saved trials
111 Michigan Ave NW
Washington, District of Columbia
(202) 476-5000
Childrens National Medical Center As the nation’s children’s hospital, the mission of Children’s National Medical...
?
mi
from
Washington,
Click here to add this to my saved trials